Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Residents of the Seventh Avenue area of Newark, New Jersey now have access to physician-level GLP-1 expertise through our telehealth platform. Our network of NJ-licensed physicians includes specialists in obesity medicine, endocrinology, and metabolic health who provide the same depth of expertise for Essex County patients that was previously only available at top-tier academic medical centers.
GLP-1 medications including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are prescribed by GLP-1-licensed physicians who understand the nuanced clinical decision-making required to optimize outcomes for Newark residents. Every treatment plan reflects clinical knowledge in GLP-1 pharmacology, patient selection, and long-term management.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 7, 2026
Semaglutide is marketed as Ozempic for type 2 diabetes management and Wegovy for chronic weight loss in adults with obesity or overweight. Licensed physicians design individualized titration schedules — escalating dose over 16–20 weeks — to maximize weight reduction while minimizing gastrointestinal side effects.
Tirzepatide simultaneously activates GLP-1 and GIP receptors, producing additive metabolic effects beyond those of single-agonist GLP-1 therapies. Mounjaro (type 2 diabetes) and Zepbound (obesity) require physician expertise in dual-receptor pharmacology and careful patient selection to optimize outcomes.
Landmark randomized controlled trials in the New England Journal of Medicine establish the efficacy profile of FDA-approved GLP-1 medications available to Seventh Avenue, Newark residents:
Telehealth prescribing of GLP-1 receptor agonists in New Jersey is conducted by board-certified, NJ-licensed physicians through HIPAA-compliant platforms. GLP-1 medications are not DEA-scheduled controlled substances and may be prescribed via telehealth after a valid clinical evaluation.
Accessing licensed GLP-1 telehealth care from Seventh Avenue follows a comprehensive, clinical protocol delivered entirely online. No need to travel to academic medical centers from Newark — our licensed physicians bring the same expertise to your screen.
Complete a thorough, clinical health questionnaire from your home in Seventh Avenue. This comprehensive assessment covers your full medical history, comorbidities, metabolic indicators, current medications, and weight management history — providing your licensed physician with the depth of information needed for clinical prescribing. Takes approximately 2-3 minutes.
A NJ-licensed licensed physician conducts a comprehensive telehealth consultation, applying GLP-1 clinical knowledge to your case. They match you with the optimal medication, design a personalized dose-escalation schedule, and establish a physician-level monitoring plan for your entire treatment journey.
Once your licensed approves your prescription, your GLP-1 medication is dispensed from a licensed US pharmacy and delivered directly to your Seventh Avenue address. Most patients in Newark receive their medication within 3-5 business days, with ongoing physician follow-up to optimize your treatment plan over time.
Our licensed telehealth physicians serve all neighborhoods in Newark and surrounding areas with the same physician-level GLP-1 protocols.
Expert GLP-1 telehealth services available across every neighborhood in Newark, NJ.
Also offering physician-level GLP-1 expertise in cities near Newark.
Physician-level GLP-1 telehealth care available in the largest cities across New Jersey.
Licensed GLP-1 telehealth physicians serve neighborhoods across all major US cities, providing the same clinical-grade care available at specialty obesity medicine centers.
Local weight loss and GLP-1 providers serving the Seventh Avenue, Newark area, based on Google Business listings.
421 Bloomfield Ave
228 S Orange Ave, South Orange Village, NJ 07079
4.9/5 ★ (29 reviews)
40 Ferry St, Newark, NJ 07105
5/5 ★ (12 reviews)
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Physicians serving Seventh Avenue and greater Newark, New Jersey specialize in obesity medicine, endocrinology, and metabolic health — not just general practitioners writing prescriptions. They hold NJ medical licenses and apply deep GLP-1 pharmacology expertise to every treatment plan, with ongoing physician-level monitoring throughout your therapy.
Licensed physicians serving Seventh Avenue and throughout Newark go beyond basic prescribing — they optimize dosing schedules, anticipate and manage side effects proactively, adjust treatment plans based on your response, and apply the latest evidence to maximize your weight loss and metabolic outcomes.
Licensed GLP-1 consultations for Newark patients are conducted through secure, HIPAA-compliant telehealth. Your licensed reviews your complete medical history, metabolic profile, and treatment goals before designing a personalized, physician-guided GLP-1 protocol with a structured follow-up plan.
Our licensed physicians prescribe all FDA-approved GLP-1 medications to eligible Essex County residents — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda) — selected based on clinical assessment of your individual metabolic profile, comorbidities, and treatment goals.
Our licensed physicians apply the same evidence-based protocols used at leading academic weight management programs. All prescriptions are issued by board-certified, NJ-licensed physicians through HIPAA-compliant platforms. Medications come from verified US pharmacies. The expertise is equivalent — the access is far greater.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
